FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770618512> ?p ?o ?g. }

• W2770618512 abstract "Introduction: Conventional anti-androgen regimens were widely used as an initiation or combined androgen blockade (CAB) therapy in advanced prostate cancer patients. Currently, new androgen pathway inhibitors such as abiraterone acetate (AA) and enzalutamide had been proven effective in metastatic castration resistant prostate cancer. In this study, we attempt to analyze the role of conventional anti-androgen drugs as deferred CAB therapy in castration-resistant prostate cancer patients. Materials and Methods: From 2012 to 2017, 48 metastatic castration-resistant prostate cancer (CRPC) patients who received sequential treatments with primary androgen blockade, oral anti-androgen regimens, and docetaxel followed by AA treatment were included. We defined effective deferred CAB as any decline of PSA after add-on antiandrogen after CRPC. Patients were separated into effective and ineffective deferred CAB. Comparison between two groups in the first line androgen deprivation therapy duration, CRPC PSA level, pre-AA PSA level, chemotherapy dosages, duration, and patients progression free survival and overall survival after AA treatment were analyzed. Results: Twenty-three patients (47.9%) achieved PSA decline after deferred CAB. Among total 48 patients, 24 patients experienced PSA decline more than 50% after AA treatment. The median PSA progression-free survival and overall survival after AA treatment in the total cohort of 48 patients were 4.4 and 24.3 months, respectively. The effective deferred CAB group showed significantly lower PSA level, lower percentage of PSA progression, higher total follow-up duration, higher percentage of surviving patients, better progression free survival, and overall survival estimate after AA treatment. Of the eight variables analyzed, effectiveness in deferred CAB showed positive association to progression free survival (HR 0.29, 95% CI 0.12-0.67, p = 0.004) and overall survival (HR 0.24, 95% CI 0.07-0.81, p = 0.022). First line androgen deprivation therapy (ADT) duration also showed positive association to overall survival (HR 0.95, 95% CI 0.91-0.99, p = 0.023). Conclusions: Effectiveness of deferred CAB therapy was positively associated with progression free survival and overall survival of AA treatment after docetaxel. It can be used as a pre-treatment predictor." @default.
• W2770618512 created "2017-12-04" @default.
• W2770618512 creator A5004447689 @default.
• W2770618512 creator A5018041820 @default.
• W2770618512 creator A5022317854 @default.
• W2770618512 creator A5024279536 @default.
• W2770618512 creator A5024399146 @default.
• W2770618512 creator A5025633982 @default.
• W2770618512 creator A5025654001 @default.
• W2770618512 creator A5033207050 @default.
• W2770618512 creator A5037179166 @default.
• W2770618512 creator A5042850501 @default.
• W2770618512 creator A5078320657 @default.
• W2770618512 creator A5086754083 @default.
• W2770618512 creator A5090736857 @default.
• W2770618512 creator A5091683814 @default.
• W2770618512 date "2017-11-22" @default.
• W2770618512 modified "2023-10-09" @default.
• W2770618512 title "Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel" @default.
• W2770618512 cites W1592598587 @default.
• W2770618512 cites W1856025141 @default.
• W2770618512 cites W1891088877 @default.
• W2770618512 cites W2055346449 @default.
• W2770618512 cites W2072037375 @default.
• W2770618512 cites W2073062381 @default.
• W2770618512 cites W2148643283 @default.
• W2770618512 cites W2166305340 @default.
• W2770618512 cites W2166918329 @default.
• W2770618512 cites W2168108459 @default.
• W2770618512 cites W2196689106 @default.
• W2770618512 cites W2239698670 @default.
• W2770618512 cites W2252849995 @default.
• W2770618512 cites W2278392405 @default.
• W2770618512 cites W2511755939 @default.
• W2770618512 cites W2588741549 @default.
• W2770618512 cites W2599467577 @default.
• W2770618512 doi "https://doi.org/10.3389/fphar.2017.00836" @default.
• W2770618512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5702804" @default.
• W2770618512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29213237" @default.
• W2770618512 hasPublicationYear "2017" @default.
• W2770618512 type Work @default.
• W2770618512 sameAs 2770618512 @default.
• W2770618512 citedByCount "5" @default.
• W2770618512 countsByYear W27706185122019 @default.
• W2770618512 countsByYear W27706185122021 @default.
• W2770618512 countsByYear W27706185122022 @default.
• W2770618512 countsByYear W27706185122023 @default.
• W2770618512 crossrefType "journal-article" @default.
• W2770618512 hasAuthorship W2770618512A5004447689 @default.
• W2770618512 hasAuthorship W2770618512A5018041820 @default.
• W2770618512 hasAuthorship W2770618512A5022317854 @default.
• W2770618512 hasAuthorship W2770618512A5024279536 @default.
• W2770618512 hasAuthorship W2770618512A5024399146 @default.
• W2770618512 hasAuthorship W2770618512A5025633982 @default.
• W2770618512 hasAuthorship W2770618512A5025654001 @default.
• W2770618512 hasAuthorship W2770618512A5033207050 @default.
• W2770618512 hasAuthorship W2770618512A5037179166 @default.
• W2770618512 hasAuthorship W2770618512A5042850501 @default.
• W2770618512 hasAuthorship W2770618512A5078320657 @default.
• W2770618512 hasAuthorship W2770618512A5086754083 @default.
• W2770618512 hasAuthorship W2770618512A5090736857 @default.
• W2770618512 hasAuthorship W2770618512A5091683814 @default.
• W2770618512 hasBestOaLocation W27706185121 @default.
• W2770618512 hasConcept C121608353 @default.
• W2770618512 hasConcept C126322002 @default.
• W2770618512 hasConcept C126894567 @default.
• W2770618512 hasConcept C143998085 @default.
• W2770618512 hasConcept C170493617 @default.
• W2770618512 hasConcept C2775832370 @default.
• W2770618512 hasConcept C2776551883 @default.
• W2770618512 hasConcept C2777899217 @default.
• W2770618512 hasConcept C2777911890 @default.
• W2770618512 hasConcept C2778468042 @default.
• W2770618512 hasConcept C2778971682 @default.
• W2770618512 hasConcept C2779322244 @default.
• W2770618512 hasConcept C2780192828 @default.
• W2770618512 hasConcept C2781190966 @default.
• W2770618512 hasConcept C61367390 @default.
• W2770618512 hasConcept C71315377 @default.
• W2770618512 hasConcept C71924100 @default.
• W2770618512 hasConceptScore W2770618512C121608353 @default.
• W2770618512 hasConceptScore W2770618512C126322002 @default.
• W2770618512 hasConceptScore W2770618512C126894567 @default.
• W2770618512 hasConceptScore W2770618512C143998085 @default.
• W2770618512 hasConceptScore W2770618512C170493617 @default.
• W2770618512 hasConceptScore W2770618512C2775832370 @default.
• W2770618512 hasConceptScore W2770618512C2776551883 @default.
• W2770618512 hasConceptScore W2770618512C2777899217 @default.
• W2770618512 hasConceptScore W2770618512C2777911890 @default.
• W2770618512 hasConceptScore W2770618512C2778468042 @default.
• W2770618512 hasConceptScore W2770618512C2778971682 @default.
• W2770618512 hasConceptScore W2770618512C2779322244 @default.
• W2770618512 hasConceptScore W2770618512C2780192828 @default.
• W2770618512 hasConceptScore W2770618512C2781190966 @default.
• W2770618512 hasConceptScore W2770618512C61367390 @default.
• W2770618512 hasConceptScore W2770618512C71315377 @default.
• W2770618512 hasConceptScore W2770618512C71924100 @default.
• W2770618512 hasLocation W27706185121 @default.
• W2770618512 hasLocation W27706185122 @default.
• W2770618512 hasLocation W27706185123 @default.

• next